rrx-001
Small moleculeexperimental
Clinical trial activity
15 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Sep 1, 2011 (NCT01359982)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Small Cell · Phase 2
- Central Nervous System Neoplasms · Phase 1
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 2
- Glioblastoma · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Neoplasms · Phase 1
- Neuroendocrine Tumors · Phase 2
- Oligodendroglioma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Small Cell Lung Carcinoma · Phase 3
- Stomatitis · Phase 2
Mechanism of action
NLRP3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CBr)N1CC([N+](=O)[O-])([N+](=O)[O-])C1- Mol. weight
- 268.02 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3526802 ↗
Also known as
- rrx-001
- rrx-001
- rrx-001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06894693 | Phase 1 | Apr 1, 2025 | China Academy of Chinese Medical Sciences, Government of China |
| NCT05966194 | Phase 2 | Dec 1, 2023 | EpicentRx, Inc. |
| NCT05566041 | Phase 3 | Aug 1, 2022 | EpicentRx, Inc. |
| NCT04525014 | Phase 1 | Sep 1, 2020 | Baylor University, EpicentRx, Inc. |
| NCT03699956 | Phase 3 | Dec 24, 2018 | EpicentRx, Inc. |
| NCT03515538 | Phase 2 | Jul 12, 2018 | Drais Pharmaceuticals, Inc., EpicentRx, Inc. |
| NCT02801097 | Phase 1 | Oct 1, 2016 | EpicentRx, Inc. |
| NCT02871843 | Phase 1 | Aug 1, 2016 | EpicentRx, Inc. |
| NCT02518958 | Phase 1 | Jul 1, 2015 | EpicentRx, Inc., United States Army |
| NCT02489903 | Phase 2 | Jun 1, 2015 | EpicentRx, Inc. |
| NCT02452970 | Phase 2 | May 1, 2015 | EpicentRx, Inc., Johns Hopkins University |
| NCT02215512 | Phase 1 | Feb 1, 2015 | EpicentRx, Inc., University of Michigan |
| NCT02096354 | Phase 2 | May 1, 2014 | EpicentRx, Inc. |
| NCT02096341 | Phase 1 | Apr 1, 2014 | EpicentRx, Inc., SCRI Development Innovations |
| NCT01359982 | Phase 1 | Sep 1, 2011 | EpicentRx, Inc., SCRI Development Innovations, University of California, San Diego |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EpicentRx, Inc. | For profit | 14 | 14 | 3 | 2011 |
| SCRI Development Innovations | For profit | 2 | 0 | 1 | 2011 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Drais Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2018 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| United States Army | Government | 1 | 0 | 1 | 2015 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2015 |
10 organizations
Page 1 / 1